Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aeglea BioTherapeutics, Inc is a biotechnology business based in the US. Aeglea BioTherapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea BioTherapeutics employs 83 staff and has a market cap (total outstanding shares value) of USD$357.2 million.
Since the stock market crash in March caused by coronavirus, Aeglea BioTherapeutics's share price has had significant positive movement.
Its last market close was USD$8.15, which is 3.44% up on its pre-crash value of USD$7.87 and 132.86% up on the lowest point reached during the March crash when the shares fell as low as USD$3.5.
If you had bought USD$1,000 worth of Aeglea BioTherapeutics shares at the start of February 2020, those shares would have been worth USD$557.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,089.57.
|Latest market close||USD$8.15|
|52-week range||USD$3.5 - USD$11.38|
|50-day moving average||USD$7.3201|
|200-day moving average||USD$7.4781|
|Wall St. target price||USD$16.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.299|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-24)||-6.75%|
|1 month (2020-10-30)||6.12%|
|3 months (2020-09-01)||10.73%|
|6 months (2020-06-01)||-8.73%|
|1 year (2019-11-29)||-4.68%|
|2 years (2018-11-30)||-3.21%|
|3 years (2017-12-01)||72.30%|
|5 years (2015-11-27)||N/A|
|Gross profit TTM||USD$-64,600,000|
|Return on assets TTM||-36.43%|
|Return on equity TTM||-66.08%|
|Market capitalisation||USD$357.2 million|
TTM: trailing 12 months
There are currently 2.8 million Aeglea BioTherapeutics shares held short by investors – that's known as Aeglea BioTherapeutics's "short interest". This figure is 6.3% up from 2.7 million last month.
There are a few different ways that this level of interest in shorting Aeglea BioTherapeutics shares can be evaluated.
Aeglea BioTherapeutics's "short interest ratio" (SIR) is the quantity of Aeglea BioTherapeutics shares currently shorted divided by the average quantity of Aeglea BioTherapeutics shares traded daily (recently around 284236). Aeglea BioTherapeutics's SIR currently stands at 10. In other words for every 100,000 Aeglea BioTherapeutics shares traded daily on the market, roughly 10000 shares are currently held short.
However Aeglea BioTherapeutics's short interest can also be evaluated against the total number of Aeglea BioTherapeutics shares, or, against the total number of tradable Aeglea BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeglea BioTherapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Aeglea BioTherapeutics shares in existence, roughly 60 shares are currently held short) or 0.0683% of the tradable shares (for every 100,000 tradable Aeglea BioTherapeutics shares, roughly 68 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Aeglea BioTherapeutics.
Find out more about how you can short Aeglea BioTherapeutics stock.
We're not expecting Aeglea BioTherapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aeglea BioTherapeutics's shares have ranged in value from as little as $3.5 up to $11.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea BioTherapeutics's is 1.8153. This would suggest that Aeglea BioTherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.